Research Use Only. Peptides Lab UK supplies research-grade materials for in-vitro laboratory research only. Nothing on this page is medical advice or an instruction for human or animal use, and no product sold on this website is a medicine.
What is Cerebrolysin?
Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids derived from porcine brain proteins. It is authorised as a medicine in some countries outside the UK; it is not an authorised medicine in the UK.
Published research
Cerebrolysin has been investigated in clinical trials in acute ischaemic stroke and vascular dementia. Cochrane systematic reviews of these trials concluded that the available evidence did not demonstrate a clear benefit on key outcomes such as mortality in acute ischaemic stroke, and they highlighted the quality limitations of the included studies. Narrative reviews describe proposed neurotrophic, multi-target mechanisms.[1,2,3]
Limitations of the evidence
Much of the available literature is preclinical (cell and animal models) or comes from small numbers of research groups. Findings in defined experimental systems cannot be extrapolated to other settings, and this page does not provide dosing, administration or human-use information.
Laboratory handling and storage
Lyophilised peptides are generally stored sealed, protected from light and moisture, at low temperature as specified on the certificate of analysis. Once reconstituted for in-vitro work, solutions are typically kept refrigerated and used within a validated stability window. Researchers should follow their institution’s procedures and the batch documentation (HPLC purity and mass-spectrometry identity) supplied with each lot.
UK regulatory status
In the UK, medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Research-grade compounds sold by Peptides Lab UK are supplied strictly for laboratory research; they are not medicinal products, are not manufactured to medicinal GMP standards and must not be used in humans or animals.
Related research pages
References
- Ziganshina LE et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2020; 7(7):CD007026. doi:10.1002/14651858.CD007026.pub6 PMID: 32662068.
- Cui S et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019; 2019(11). doi:10.1002/14651858.CD008900.pub3 PMID: 31710397.
- Brainin M et al. Cerebrolysin: a multi-target drug for recovery after stroke. Expert Rev Neurother. 2018; 18(8):681-687. doi:10.1080/14737175.2018.1500459 PMID: 30004268.
Disclaimer: All products sold by Peptides Lab UK are for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.
